Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernovartis.com
English RSS Feed
Get the latest updates from English RSS Feed directly as they happen.
Follow now 76 followers
Latest posts
Last updated 7 days ago
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
7 days ago
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with...
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
7 days ago
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain...
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
21 days ago
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH...
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
21 days ago
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for...
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
26 days ago
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by...
Novartis announces plans to build flagship manufacturing hub in North Carolina
26 days ago
Novartis announces plans to build flagship manufacturing hub in North Carolina arcticnovartis...
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
29 days ago
Novartis ianalumab first drug to reduce disease activity and patient burden in...
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
29 days ago
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate...
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
29 days ago
Novartis opens new radioligand therapy manufacturing facility in California as part of...
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
29 days ago
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary...
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
about 1 month ago
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary...
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
about 1 month ago
Novartis opens new radioligand therapy manufacturing facility in California as part of...